Article
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
Viruses - 7 Dec 2015
Porter Danielle P, Daeumer Martin, Thielen Alexander, Chang Silvia, Martin Ross, Cohen Cal, Miller Michael D, White Kirsten L
Abstract excerpt
At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population sequencing. Furthermore, more RPV/FTC/TDF-treated subjects with baseline HIV-1 RNA >100,000 copies/mL developed resistance compared to subjects with baseline HIV-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.